Halozyme Therapeutics (HALO) reiterated full year 2024 financial guidance and increased full year 2025 and multi-year financial guidance. For 2025, the company now expects: non-GAAP EPS in a range of $4.95 to $5.35, revised from prior guidance range of $4.45 to $4.85. Total revenue is now expected in a range of $1.15 billion to $1.225 billion, revised from prior guidance range of $1.095 billion to $1.17 billion.
Preliminary estimates of results for the twelve months ended December 31, 2024, include: Non-GAAP EPS in a range of $4.00 to $4.20; and total revenue in a range of $970 million to $1.02 billion.
The company also announced it has recently entered into a new $250 million accelerated share repurchase program under previously announced $750 million share repurchase program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.